A novel TRP score based on four genes (TTK, EPO, SLC7A11, PON1) accurately predicts TACE refractoriness and prognosis in HCC, identifying tumors with immunosuppressive phenotypes and guiding therapy decisions, including ICIs and sorafenib. This evidence concerns the gene EPO and hepatocellular carcinoma.